RenovoRx TAMP™ Pre-Clinical Results to Be Awarded at SIR 2025
RenovoRx TAMP™ Pre-Clinical Results to Be Awarded at SIR 2025 RenovoRx, Inc. (“RenovoRx” or the “Company”), a pioneering life sciences company dedicated to advancing targeted oncology therapies, is pleased to…
Merck Licenses HRS-5346 for Cardiovascular Disease from Hengrui
Merck Licenses HRS-5346 for Cardiovascular Disease from Hengrui Merck, known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a leading global…
Xcellbio Partners with Planet Innovation to Advance Cell Therapy Manufacturing
Xcell Biosciences Partners with Planet Innovation and Royal Perth Hospital to Advance Cell Therapy Manufacturing Xcell Biosciences Australia Pty Ltd (Xcellbio), a subsidiary of the San Francisco-based biotechnology company specializing…
FDA Approves Blujepa (Gepotidacin) for uUTIs in Adults & Teens
FDA Approves Blujepa (Gepotidacin) for uUTIs in Adults & Teens GSK plc has announced that the US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of…
Veracyte’s WGS-Based MRD Test Shows Accuracy in Bladder Cancer
Veracyte’s Whole-Genome Sequencing-Based MRD Test Shows High Accuracy for Muscle-Invasive Bladder Cancer Detection Veracyte, Inc., a leader in cancer diagnostics, has announced groundbreaking new data demonstrating the accuracy and effectiveness…
$13.5B Oligonucleotide Synthesis Market Outlook to 2035: Pharma & Biopharma Dominate
$13.5B Oligonucleotide Synthesis Market Outlook to 2035: Pharma & Biopharma Dominate The global oligonucleotide synthesis market is poised for significant growth, expanding from USD 4.8 billion in the current year…
Dr. Mike Graham Named Head of R&D at Bayer Crop Science
Dr. Mike Graham Named Head of R&D at Bayer Crop Science Bayer has officially announced that Dr. Mike Graham will assume the role of Head of Research & Development (R&D)…
Quince Therapeutics Shares Business Update & 2024 Financial Results
Quince Therapeutics Shares Business Update & 2024 Financial Results Quince Therapeutics, Inc., a late-stage biotechnology company focused on leveraging a patient’s own biology to treat rare diseases, has provided an…
CEL-SCI: Multikine Boosts Quality of Life by Up to 95% in Head & Neck Cancer Patients
CEL-SCI: Multikine Boosts Quality of Life by Up to 95% in Head & Neck Cancer Patients CEL-SCI Corporation (NYSE American: CVM) has recently announced the publication of new data from…
Neurogene Announces Q4 & Full-Year 2024 Results, Updates
Neurogene Announces Q4 & Full-Year 2024 Results, Updates Neurogene Inc., a clinical-stage company dedicated to developing life-changing genetic medicines for patients and families affected by rare neurological diseases, has announced…
IFF Pharma Showcases Next-Gen Excipients at CPHI Japan 2025
IFF Pharma Showcases Next-Gen Excipients at CPHI Japan 2025 IFF Pharma Solutions is set to showcase its latest cutting-edge excipient technologies at CPHI Japan 2025, reinforcing its commitment to revolutionizing…
Pearsanta Acquires Adductomics Tech for Early Cancer Detection
Pearsanta Acquires Adductomics Tech for Cancer Risk Monitoring Aditxt, Inc. (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, has announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”),…